AGL 36.51 Decreased By ▼ -1.49 (-3.92%)
AIRLINK 216.01 Increased By ▲ 2.10 (0.98%)
BOP 9.46 Increased By ▲ 0.04 (0.42%)
CNERGY 6.59 Increased By ▲ 0.30 (4.77%)
DCL 8.50 Decreased By ▼ -0.27 (-3.08%)
DFML 40.90 Decreased By ▼ -1.31 (-3.1%)
DGKC 99.48 Increased By ▲ 5.36 (5.69%)
FCCL 36.48 Increased By ▲ 1.29 (3.67%)
FFBL 88.94 No Change ▼ 0.00 (0%)
FFL 17.17 Increased By ▲ 0.78 (4.76%)
HUBC 126.25 Decreased By ▼ -0.65 (-0.51%)
HUMNL 13.35 Decreased By ▼ -0.02 (-0.15%)
KEL 5.24 Decreased By ▼ -0.07 (-1.32%)
KOSM 6.71 Decreased By ▼ -0.23 (-3.31%)
MLCF 44.24 Increased By ▲ 1.26 (2.93%)
NBP 60.50 Increased By ▲ 1.65 (2.8%)
OGDC 222.49 Increased By ▲ 3.07 (1.4%)
PAEL 40.60 Increased By ▲ 1.44 (3.68%)
PIBTL 8.16 Decreased By ▼ -0.02 (-0.24%)
PPL 191.99 Increased By ▲ 0.33 (0.17%)
PRL 38.60 Increased By ▲ 0.68 (1.79%)
PTC 27.00 Increased By ▲ 0.66 (2.51%)
SEARL 103.50 Decreased By ▼ -0.50 (-0.48%)
TELE 8.62 Increased By ▲ 0.23 (2.74%)
TOMCL 34.86 Increased By ▲ 0.11 (0.32%)
TPLP 13.60 Increased By ▲ 0.72 (5.59%)
TREET 24.99 Decreased By ▼ -0.35 (-1.38%)
TRG 71.99 Increased By ▲ 1.54 (2.19%)
UNITY 33.33 Decreased By ▼ -0.06 (-0.18%)
WTL 1.72 No Change ▼ 0.00 (0%)
BR100 11,987 Increased By 93.1 (0.78%)
BR30 37,178 Increased By 323.2 (0.88%)
KSE100 111,351 Increased By 927.9 (0.84%)
KSE30 35,039 Increased By 261 (0.75%)

GlaxoSmithKline's prospective two-monthly two-drug injection to treat HIV was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, the British drugmaker said on Thursday.

The long-acting needle-based combination of its drug cabotegravir and Janssen's treatment rilpivirine met its main goal in the study, which was testing the regimen in adults with HIV-1 whose virus was suppressed.

The patients were also not resistant to either of the two drugs, said ViiV Healthcare, London-listed GSK's HIV unit.

"This is further progress in our efforts to reduce the number of medicines a person living with HIV must take while also reducing the frequency of treatments," said Kimberly Smith, Head of Research & Development at ViiV.

Current HIV treatments include three-drug daily oral pills and two-drug pills. The latest study shows people with HIV could maintain viral suppression with six treatments per year, thereby reducing toxicity from the number of drugs they have to take.

The HIV-1 category has the most widespread strains of the AIDS-causing virus, which severely affects the body's immune system.

Janssen, U.S.-based Johnson & Johnson's pharmaceuticals unit, also announced the results from the study in a separate statement and said further details will be presented at a scientific meeting.

The results from the study also boost GSK's prospects against Gilead Sciences, the U.S. drugmaker that dominates the HIV market, as ViiV works to develop shorter therapies.

Pfizer and Japan's Shionogi also hold stakes in ViiV.

Copyright Reuters, 2019

Comments

Comments are closed.